CN113117241B - Magnetic field generating device for improving insulin level and sensitivity and application thereof - Google Patents
Magnetic field generating device for improving insulin level and sensitivity and application thereof Download PDFInfo
- Publication number
- CN113117241B CN113117241B CN202110407702.1A CN202110407702A CN113117241B CN 113117241 B CN113117241 B CN 113117241B CN 202110407702 A CN202110407702 A CN 202110407702A CN 113117241 B CN113117241 B CN 113117241B
- Authority
- CN
- China
- Prior art keywords
- magnetic
- magnetic field
- generating device
- mice
- field generating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N2/00—Magnetotherapy
- A61N2/06—Magnetotherapy using magnetic fields produced by permanent magnets
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses a magnetic field generating device for improving insulin level and sensitivity, which relates to the technical field of magnetic fields and comprises a magnetic body unit, wherein the magnetic body unit comprises magnetic particles, a substrate and an accommodating main body, the substrate is in a sheet shape, a plurality of convex magnetic bags are arranged on the substrate, the magnetic particles are wrapped in the magnetic bags, and the magnetic particles are arranged on the substrate in a matrix manner; the number of the magnetic body units is 10-12, and the magnetic particles in each magnetic body unit are distributed in two rows and four columns; or the number of the magnetic body units is 1, and the magnetic particles in the magnetic body units are distributed in twelve rows and eight columns or ten rows and eight columns; the accommodating main body is positioned on the magnetic bag; the magnetic poles of any magnetic particles are the same, and the magnetic field intensity of the magnetic field generating device is 0.5T at most. The invention also provides the application of the device. The invention has the beneficial effects that: the magnetic field generating device has the functions of reducing blood sugar, improving insulin level and obviously improving insulin resistance and insulin sensitivity.
Description
Technical Field
The invention relates to the technical field of magnetic fields, in particular to a magnetic field generating device for improving insulin level and sensitivity and application thereof.
Background
The rapid development of biomagnetism and magnetobiology research is closely related to the rapid progress of material science. For example, patent publication No. CN208694048U discloses a medical permanent magnet therapeutic device, and patent publication No. CN201353378Y discloses a low-frequency rotating permanent magnet strong magnetic field therapeutic device. Patent application publication No. CN111411041A discloses a gyromagnetic cell culture apparatus and its application, which can inhibit the metastasis of breast cancer cells by using the gyromagnetic cell culture apparatus.
Patent application publication No. CN111408051A discloses a magnetic field generating device for regulating blood glucose level and its application, which can regulate blood glucose level and improve iron metabolism, thereby participating in reducing glucose level in hepatoma cells.
However, the patent of CN111408051A shows no blood sugar lowering effect after the magnetic field direction is changed and the device has no blood sugar lowering effect on mice with high blood sugar obesity induced by high fat diet. Therefore, how to develop and optimize a magnetic field generating device which can improve insulin level and increase insulin sensitivity in hyperglycemia obesity mice so as to reduce blood sugar level is helpful for researching the action mechanism of the magnetic field generating device, and further deepens the understanding of the magnetic field and expands the future practical application of the magnetic field.
Disclosure of Invention
The technical problem to be solved by the invention is that the S pole of the magnetic particle in the magnetic field generating device in the prior art participates in reducing the level of glucose in liver cancer cells, and the N pole has the function of increasing blood sugar, and the N pole and the S pole in the magnetic field generating device can both improve the level and the sensitivity of insulin.
The invention solves the technical problems through the following technical means:
a magnetic field generating device for improving insulin level and sensitivity comprises a magnetic body unit, wherein the magnetic body unit comprises magnetic particles, a substrate and an accommodating main body, the substrate is sheet-shaped, a plurality of convex magnetic packets are arranged on the substrate, the magnetic particles are wrapped in the magnetic packets, and the magnetic particles are arranged on the substrate in a matrix manner;
the magnetic particles comprise a cylindrical base body, the upper bottom surface of the base body is integrally connected with a magnet gathering body positioned above the base body, the area of each cross section of the magnet gathering body in the horizontal direction from the bottom surface connected with the upper bottom surface of the base body to at least two thirds of the height of the magnet gathering body is gradually reduced from bottom to top, and the height of the magnet gathering body is smaller than that of the base body;
the number of the magnetic units is 10-12, and the magnetic particles in each magnetic unit are distributed in two rows and four columns; or the number of the magnetic units is 1, and the magnetic particles in the magnetic units are distributed in twelve rows and eight columns or ten rows and eight columns; the accommodating main body is positioned on the magnetic bag; the magnetic poles of any magnetic particles are the same, and the magnetic field intensity of the magnetic field generating device is 0.5T at most.
Has the advantages that: the magnetic field generating device has the functions of reducing blood sugar, improving insulin level and obviously improving insulin resistance and insulin sensitivity.
Preferably, the substrate is located on the supporting plate, and an adhesive layer is arranged between the substrate and the supporting plate.
Preferably, the containment body is a cage.
The invention also provides an application of the magnetic field generating device in constructing a hypoglycemia and obesity mouse model for non-treatment purposes, which comprises the following steps:
(1) feeding mouse high fat diet feed, and after feeding for one week, placing the mouse in the containing body with the N pole or S pole of the magnetic particles facing the mouse;
(2) mice were continuously fed with high fat diet for 8 weeks.
Has the advantages that: after the magnetic field generating device is used for processing, the blood sugar of the obese mouse is obviously reduced, the early-stage blood sugar level of type II diabetes (T2DM) can be reduced, and the insulin level and the sensitivity of the hypoglycemic obese mouse constructed simultaneously after the treatment of the magnetic field generating device are increased, so that the hypoglycemic obese mouse can be constructed, the further research on the hypoglycemic obese mouse is facilitated, the understanding of the magnetic field is deepened, and the application of the magnetic field is expanded.
Preferably, the high fat diet feed is 60% kcal high fat feed.
The invention has the advantages that: the magnetic field generating device has the functions of reducing blood sugar, improving insulin level and obviously improving insulin resistance and insulin sensitivity.
The magnetic field generating device can be used for constructing the hypoglycemia obese mouse, can reduce the early-stage blood sugar level of type II diabetes (T2DM), is favorable for further research on the hypoglycemia obese mouse, deepens the understanding of the magnetic field and expands the application of the magnetic field.
Drawings
FIG. 1 is a schematic structural view of a magnetic body unit in embodiment 1 of the present invention;
FIG. 2 is a schematic view showing the structure of a magnetic particle in example 1 of the present invention;
FIG. 3 is a schematic view showing the structure of a magnetic field generating apparatus for improving insulin level and sensitivity in example 1 of the present invention;
FIG. 4 is another schematic view of the structure of the magnetic field generating device for improving insulin level and sensitivity according to embodiment 1 of the present invention;
FIG. 5 is a schematic view showing the structure of a magnetic field generating apparatus for improving insulin level and sensitivity according to example 2 of the present invention;
FIG. 6 is another schematic view of the structure of the magnetic field generating device for improving insulin level and sensitivity according to embodiment 2 of the present invention;
FIG. 7 is a magnetic field distribution diagram of the surface of the S-pole magnetic particles of the magnetic body unit in FIG. 1; s is a downward direction in the figure;
FIG. 8 is a magnetic field distribution diagram of the surface of the S-pole magnetic particles of the magnetic field generating device in FIG. 4; s is a downward direction in the figure;
FIG. 9 is a magnetic field distribution diagram of the surface of N-pole magnetic particles of the magnetic body unit in FIG. 1; in the figure, N is an upward direction;
FIG. 10 is a magnetic field distribution diagram of the surface of N-pole magnetic particles of the magnetic field generator in FIG. 4; in the figure, N is an upward direction;
FIG. 11 is a graph showing the relationship between the week age and the body weight of each group of mice in example 3 of the present invention;
FIG. 12 is a graph showing the relationship between the week age of each group of mice and the change in blood glucose level in example 3 of the present invention;
FIG. 13 is a bar graph showing the relationship between the changes in serum insulin levels in the mice of each group in example 3 of the present invention;
FIG. 14 is a bar graph comparing food intake for groups of mice in example 3 of the present invention;
FIG. 15 is a bar graph comparing the water intake of groups of mice in example 3 of the present invention;
FIG. 16 is a graph comparing the area under the curve (AUC) of a glucose tolerance test after intraperitoneal injection of glucose in each group of mice in example 3 of the present invention; (ii) a
FIG. 17 is a graph comparing the area under the curve (AUC) of the insulin tolerance test after intraperitoneal injection of insulin into each group of mice in example 3 of the present invention;
FIG. 18 is a graph showing a comparison of insulin sensitivity indexes of groups of mice in example 3 of the present invention;
FIG. 19 is a graph showing a comparison of insulin resistance in each group of mice in example 3 of the present invention;
FIG. 20 is a graph comparing the function of islet beta cells of mice in each group according to example 3 of the present invention;
FIG. 21 is a graph showing the effect of the magnetic field generating device of FIGS. 3 and 4 on blood glucose in a mouse;
FIG. 22 is a magnetic field pattern of the S pole of the magnetic field generating apparatus in comparative example 1 of the present invention; s is a downward direction in the figure;
FIG. 23 is a N-pole magnetic field pattern of the magnetic field generating device of comparative example 1 of the present invention; in the figure, N is an upward direction;
FIG. 24 is a graph showing the results of blood glucose measurement in an obese mouse model constructed by the magnetic field generating device of comparative example 1 according to the present invention;
FIG. 25 is a magnetic field intensity distribution diagram of a magnetic field generating apparatus in comparative example 2 of the present invention;
FIG. 26 is a magnetic field intensity distribution diagram of a magnetic field generating apparatus in comparative example 3 of the present invention;
FIG. 27 is a graph showing the results of blood glucose measurement of each group of mice in comparative example 2 of the present invention;
FIG. 28 is a graph showing the relationship between the blood glucose level with time after intraperitoneal injection of glucose into each group of mice in comparative example 2 (left graph) and a graph showing the comparison between the area under the curve and the AUC (right graph);
FIG. 29 is a bar graph showing the body weight changes of the groups of mice in comparative example 2 of the present invention;
FIG. 30 is a bar graph of the change in food intake and water intake of groups of mice in comparative example 2 of the present invention;
in the figure: a magnetic body unit 1; magnetic particles 11; a magnetism collecting body 111; a base 112; a substrate 12; and a magnetic package 13.
Detailed Description
In order to make the objects, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the embodiments of the present invention, and it is obvious that the described embodiments are some embodiments of the present invention, but not all embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Test materials, reagents and the like used in the following examples are commercially available unless otherwise specified.
The specific techniques or conditions not specified in the examples can be performed according to the techniques or conditions described in the literature in the field or according to the product specification.
Example 1
A magnetic field generating device for improving insulin level and sensitivity, as shown in fig. 1-2, comprises a magnetic body unit 1, the magnetic body unit 1 comprises magnetic particles 11, a substrate 12 and a containing body, the substrate 12 is sheet-shaped, a plurality of convex magnetic envelopes 13 are arranged on the substrate 12, the magnetic particles 11 are wrapped in the magnetic envelopes 13, and the magnetic particles 11 are arranged on the substrate 12 in a matrix;
the magnetic particles 11 comprise a cylindrical base body 112, a magnetism gathering body 111 positioned above the base body 112 is integrally connected to the upper bottom surface of the base body 112, the area of each cross section of the magnetism gathering body 111 in the horizontal direction from the bottom surface connected to the upper bottom surface of the base body 112 to at least two thirds of the height of the magnetism gathering body is gradually reduced from bottom to top, and the height of the magnetism gathering body 111 is smaller than that of the base body 112. The magnetism collecting body 111 is in a circular convex shape, the radius of the horizontal cross section of the bottommost of the magnetism collecting body 111 is more than 1.5 times of the height of the base body 112, and the height of the base body 112 is more than 1.5 times of the height of the magnetism collecting body 111. The magnetic body unit 1 in this embodiment is the same as the strong magnetic field generating device disclosed in patent publication No. CN 106345063A.
As shown in fig. 3 and 4, the magnetic field generating device in this embodiment is formed by splicing a plurality of magnetic body units 1, the magnetic body units 1 are fixed on a supporting plate (not shown) by a double-sided tape, the number of the magnetic body units 1 in this embodiment is 10 or 12, the magnetic particles 11 in each magnetic body unit 1 are distributed in two rows and four columns, and the total number of the magnetic particles 11 is 80 or 96.
The distance between the magnetic particles in this example was 3cm, and the size of the magnetic body unit 1 was (length 11.5cm, width 6cm, height 0.8 cm). When the magnetic body unit 1 is composed of 10 or 12 pieces, respectively: the device dimensions were respectively: 30cm by 23cm by 0.8cm and 36cm by 23cm by 0.8 cm. The distance between the magnetic particles, the size of the device has no influence on the surface magnetic field strength.
Example 2
This embodiment is different from embodiment 1 in that: as shown in fig. 5 and 6, the number of the magnetic body units 1 is 1, the magnetic particles 11 in the magnetic body units 1 are distributed in twelve rows and eight columns or ten rows and eight columns, and the total number of the magnetic particles 11 is 80 or 96.
In this embodiment the holding body is a cage which is placed on a magnetic pack 13 with the S-pole or N-pole of the magnetic particles disposed towards the cage.
With the ground as a horizontal plane, the S-pole magnetic body units 1 (two rows and four columns) face downward, the magnetic field distribution pattern on the surface of the magnetic particles is shown in fig. 7, and when 12 magnetic body units 1 are spliced together, the magnetic field distribution on the surface is shown in fig. 8. The magnetic field strength of the magnetic field generating device of this embodiment was determined to be about 0.5T at maximum.
With the ground as a horizontal plane, the N-pole magnetic body units 1 (two rows and four columns) face upward, the magnetic field distribution pattern on the surface of the magnetic particles is shown in fig. 9, and when 12 magnetic body units 1 are spliced together, the magnetic field distribution on the surface is shown in fig. 10. The magnetic field strength of the magnetic field generating device of this embodiment was determined to be about 0.5T at maximum.
The magnetic field gradient is larger and the magnetic flux is higher than in the patent application published under the number CN 111408051A.
Example 3
The effect of the magnetic field generator of example 1 on an obese mouse that does not develop diabetes can be further explained by constructing a hypoglycemic obesity mouse model using the magnetic field generator of example 1.
Step one, C57BL/6J mice of 5 weeks of age were used as study subjects and fed for 1 week.
And step two, dividing the mice fed for 1 week in the step one into four groups, namely a first group of mice, a second group of mice, a third group of mice and a fourth group of mice. Specifically, mice from each group were individually placed in their respective cages (i.e., mouse cages).
The magnetic field generating device comprises a first magnetic field generating device and a second magnetic field generating device, wherein the magnetic particles 11 in the first magnetic field generating device are N poles, and the magnetic particles 11 in the second magnetic field generating device are S poles. A control group was also set, including a blank control device.
The blank contrast device comprises a third mouse cage and a supporting plate, wherein the third mouse cage is arranged on the supporting plate, and specifically, a third group of mice can be placed in the third mouse cage and are placed on the supporting plate together. The third cage of the invention can also be arranged on the supporting plate by means of screw-fitting, welding, anchoring and the like in the prior art. The pallet of the present invention uses iron plates or other non-magnetic prior art pallets as a blank control.
The time for treating the first group of mice by the first magnetic field generating device and the time for treating the second group of mice by the second magnetic field generating device are both 24 h/day, namely the first group of mice and the second group of mice are always positioned on the respective neodymium iron boron permanent magnets within 24h every day, and the third group of mice are positioned on the iron plates of the blank control device 24h every day. Meanwhile, after 1 week of feeding in step one, the first, second and third groups of mice were continuously fed with high fat diet D12492, and the fourth group of mice was fed with normal diet.
After feeding for one week in the first step, the first group of mice, the second group of mice and the third group of mice are respectively placed on the magnetic bag 13 with the mouse cages (i.e. the first mouse cage, the second mouse cage and the third mouse cage) of each group of mice loaded.
And step three, continuously feeding the first group of mice, the second group of mice and the third group of mice with the high-fat diet D12492, and then, after 8 weeks, namely, 14-week-old mice.
And step four, the treatment time of the magnetic field generating device lasts for 8 weeks, namely the week age of the mice is 14 weeks.
The above examples resulted in a high fat diet N-pole treated group (first group of mice), a high fat diet S-pole treated group (second group of mice), a high fat diet control group without magnet treatment (third group of mice), and a normal diet control group without magnet treatment (fourth group of mice).
In this example, the 60% kcal high fat diet selected was D12492, available from Research Diets. None of the first, second, third and fourth groups of mice developed diabetes.
And (3) detecting physiological indexes of the mice: the weight and blood glucose values of the mice in each group are counted 1 time per week, the drinking water and food consumption are counted 3 times per week, and the average drinking water and food consumption of each mouse in each day are respectively calculated.
Glucose tolerance assay experiment: at the age of 13 weeks, obese mice were intraperitoneally injected with a D- (+) -glucose solution (wherein D- (+) -glucose was purchased from shanghai institute of technology, cat # a600219, the solvent was water, and the mass volume percentage m/v of D- (+) -glucose in the D- (+) -glucose solution was 20%) at a dose of 1.0 g/kg/mouse, and the blood glucose values of the mice were measured at 30, 60, 90 and 120min before and after injection, respectively.
Insulin sensitivity assay: at the age of 14 weeks, obese mice were injected intraperitoneally with insulin solution (purchased from Novonide, original concentration 300IU/3mL) at a dose of 0.75 IU/kg/mouse, and the blood glucose values of the mice were measured at 30, 60, 90 and 120min before and after injection, respectively.
HOMA (Homeostasis Model Association, Steady State Model): at the age of 14 weeks, obese mice were fasted overnight for 12h without water deprivation. Through retroorbital venous plexus blood sampling, the following three HOMA parameters are respectively calculated:
HOMA-ISI (insulin sensitivity index) ═ Ln [ 1/(post-fasting insulin content (mU/L) × post-fasting blood glucose level (mmol/L) ];
HOMA-IR (insulin resistance) ([ insulin content after fasting (mU/L) × blood glucose level after fasting (mmol/L) ]/22.5;
HOMA- β (islet β cell function) [ (20 × (insulin content after fasting (mU/L) ]/[ blood glucose level after fasting (mmol/L) -3.5 ].
The experimental results are as follows:
1) as shown in fig. 11, the body weight of the mice in the high-fat diet group (first group of mice, second group of mice, third group of mice) was significantly higher than that of the mice in the normal diet control group (fourth group of mice); mice in the high-fat diet N-pole treated group (first group of mice) had a slightly lower body weight than mice in the high-fat diet control group (third group of mice); the high-fat diet S-pole treated group (second group of mice) had a higher body weight than the high-fat diet control group of mice (third group of mice).
2) As shown in fig. 12, blood glucose levels of mice in the high fat diet N-pole treated group and S-pole treated group were significantly reduced compared to the high fat diet control group; the blood sugar reducing ability of the mice in the N-pole treatment group is about 33.7 percent, and the blood sugar values of the mice in the high-fat diet group are higher than those of the mice in the normal diet group.
3) As shown in fig. 13, mice in the high-fat diet N-pole treated group and the high-fat diet S-pole treated group had elevated serum insulin levels in the fat diet control group; the blood sugar value of the mice in the high-fat diet group is lower than that of the mice in the normal diet group. Insulin levels were increased by 22.3% in the S-treated group relative to the control group.
4) As shown in fig. 14, the mice on the high fat diet all ingested less than the mice on the normal diet control group.
5) As shown in fig. 15, the water consumption of mice in the high-fat drinking group was lower than that of the mice in the normal diet control group; mice in the high-fat diet S pole treated group had significantly lower water consumption than mice in the high-fat diet control group.
6) As shown in fig. 16, in the glucose tolerance test by intraperitoneal injection, the control group with higher blood sugar content and fat content in the mice treated with high fat diet S phase was significantly reduced; the blood glucose content of the mice in the high-fat diet group is obviously higher than that of the mice in the normal diet group.
7) As shown in fig. 17, in the experiment of detecting insulin sensitivity by intraperitoneal injection, the mice in the high-fat diet N-pole treated group and the mice in the high-fat diet S-pole treated group had significantly decreased blood glucose content; the blood glucose content of the high-fat diet group is obviously higher than that of the normal diet group mice.
8) As shown in fig. 18, the insulin sensitivity index was significantly increased in the high fat diet N-pole treated mice and the high fat diet S-pole treated mice compared to the high fat diet control group.
9) As shown in fig. 19, the high fat diet S pole treated group mice had an increased insulin resistance index compared to the high fat diet control mice; the insulin resistance index was significantly increased in mice in the high-fat diet S-pole treated group compared to mice in the high-fat diet N-pole treated group.
10) As shown in fig. 20, islet β cell function was significantly increased in mice of the high-fat diet N-pole treated group and mice of the high-fat diet S-pole treated group as compared to the high-fat diet control group.
11) As shown in fig. 21, the magnetic field generating devices comprising 10 to 12 magnetic units 1 (with N or S poles facing upward) had the same effect on blood glucose levels in mice, and no significant difference was observed.
In conclusion, the magnetic field generating device can reduce the early-stage blood sugar level of type II diabetes (T2DM), so that a hypoglycemic obesity mouse is constructed, further research on the hypoglycemic obesity mouse is facilitated, understanding of the magnetic field is deepened, and the application of the magnetic field is expanded.
The N pole and the S pole of the magnetic field generating device have the functions of reducing blood sugar, improving insulin level and obviously improving insulin resistance and insulin sensitivity.
When the obese mouse is further induced to form a T2DM model, the magnetic field generating device reduces blood sugar, improves insulin level and sensitivity, and has better blood sugar reduction effect and insulin sensitivity improvement level than the CN111408051A in the prior art.
Comparative example 1
This comparative example differs from example 2 in that: the magnetic field generating device in the prior art CN111408051A is adopted.
The experimental results are as follows: fig. 22 and 23 are magnetic field distribution diagrams of the S pole and the N pole of the magnetic field generating device in CN111408051A, respectively. As can be seen, the magnetic field strength of the surface of the magnetic field generating device is about 2000Gs at maximum, and the magnetic field strength is about 0.2T.
As shown in fig. 24, after the N-pole treatment and the S-pole treatment, the blood sugar of the mice before diabetes is formed is not reduced, but is increased, so that a hypoglycemia obesity mouse model cannot be constructed by using the magnetic field generating device in the prior art CN 111408051A.
Comparative example 2
This comparative example differs from example 1 in that: n and S pole magnetic particles are alternately arranged, 24 cylindrical permanent magnets with the diameter multiplied by the height multiplied by 10 multiplied by 15mm are alternately arranged in the N pole and the S pole, the distance between the adjacent magnetic particles is 35mm, and the magnetic poles of the permanent magnets at diagonal positions face in the same direction. Finally, the magnetic field generating device with N and S pole magnetic particles alternately arranged is formed, wherein the length of the magnetic field generating device is 376mm, the width of the magnetic field generating device is 266mm, and the height of the magnetic field generating device is 20 mm. The size of the magnetic field generating device has no influence on the magnetic field intensity. As shown in fig. 25 and 26, the magnetic field intensity on the surface of the magnetic field generating device is 0.4T or 0.6T, respectively, depending on the magnetic field intensity when the magnetic particles are magnetized.
A mouse model of type II diabetes was constructed using the method of patent application publication No. CN111408051A, example 2, except that 8 weeks high fat diet + STZ was used to induce diabetes.
As shown in fig. 27-30, the two magnetic fields in comparative example 2 and comparative example 3 had no effect on blood glucose of T2DM mice, no significant difference in glucose tolerance of T2DM mice, no significant difference in body weight of T2DM mice, and no significant difference in diet and water intake of T2DM mice.
The above examples are only intended to illustrate the technical solution of the present invention, but not to limit it; although the present invention has been described in detail with reference to the foregoing embodiments, it will be understood by those of ordinary skill in the art that: the technical solutions described in the foregoing embodiments may still be modified, or some technical features may be equivalently replaced; and such modifications or substitutions do not depart from the spirit and scope of the corresponding technical solutions of the embodiments of the present invention.
Claims (4)
1. A magnetic field generating device for increasing insulin level and sensitivity, comprising: the magnetic particle packaging device comprises a magnetic body unit, wherein the magnetic body unit comprises magnetic particles, a substrate and an accommodating main body, the substrate is flaky, a plurality of convex magnetic packages are arranged on the substrate, the magnetic particles are wrapped in the magnetic packages, and the magnetic particles are arranged on the substrate in a matrix manner;
the magnetic particles comprise a cylindrical base body, the upper bottom surface of the base body is integrally connected with a magnet gathering body positioned above the base body, the area of each cross section of the magnet gathering body in the horizontal direction from the bottom surface connected with the upper bottom surface of the base body to at least two thirds of the height of the magnet gathering body is gradually reduced from bottom to top, and the height of the magnet gathering body is smaller than that of the base body;
the number of the magnetic units is 10-12, and the magnetic particles in each magnetic unit are distributed in two rows and four columns; or the number of the magnetic units is 1, and the magnetic particles in the magnetic units are distributed in twelve rows and eight columns or ten rows and eight columns; the accommodating main body is positioned on the magnetic bag; the magnetic poles of any magnetic particles are the same, and the magnetic field intensity of the magnetic field generating device is 0.5T at most.
2. The magnetic field generating device for increasing insulin level and sensitivity according to claim 1, wherein: the base plate is positioned on the supporting plate, and an adhesive layer is arranged between the base plate and the supporting plate.
3. The magnetic field generating device for increasing insulin level and sensitivity according to claim 1, wherein: the containment body is a cage.
4. Use of a magnetic field generating device according to any one of claims 1 to 3 for the construction of a hypoglycaemic obesity mouse model for non-therapeutic purposes, characterized in that: the method comprises the following steps:
(1) feeding mouse high fat diet feed, and after feeding for one week, placing the mouse in the containing body with the N pole or S pole of the magnetic particles facing the mouse;
(2) mice were continuously fed with high fat diet for 8 weeks.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110407702.1A CN113117241B (en) | 2021-04-15 | 2021-04-15 | Magnetic field generating device for improving insulin level and sensitivity and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110407702.1A CN113117241B (en) | 2021-04-15 | 2021-04-15 | Magnetic field generating device for improving insulin level and sensitivity and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113117241A CN113117241A (en) | 2021-07-16 |
| CN113117241B true CN113117241B (en) | 2022-01-28 |
Family
ID=76777332
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110407702.1A Active CN113117241B (en) | 2021-04-15 | 2021-04-15 | Magnetic field generating device for improving insulin level and sensitivity and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113117241B (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106345063A (en) * | 2016-08-31 | 2017-01-25 | 浙江和也健康科技有限公司 | Waist magnetic therapy device |
| CN206057340U (en) * | 2016-09-18 | 2017-03-29 | 姜涛 | A kind of diabetic therapy detection means |
| CN108210724A (en) * | 2018-02-05 | 2018-06-29 | 李春伸 | A kind of biological magnetic Chinese medicine for treating diabetes and preparation method thereof |
| CN110585163A (en) * | 2019-09-25 | 2019-12-20 | 万平 | Medical instrument |
| CN111408051A (en) * | 2020-03-31 | 2020-07-14 | 中国科学院合肥物质科学研究院 | Magnetic field generating device for adjusting blood glucose level and application thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2741034C (en) * | 2008-10-20 | 2021-06-22 | Liposcience, Inc. | Lipoprotein insulin resistance indexes and related methods, systems and computer programs for generating same |
| WO2013117681A1 (en) * | 2012-02-10 | 2013-08-15 | Alere Switzerland Gmbh | Assay and method for determining insulin-resistance |
| CA3118629A1 (en) * | 2018-11-05 | 2020-05-14 | Balticgruppen Bio Ab | Methods of treating diabetes in severe insulin-resistant diabetic subjects |
-
2021
- 2021-04-15 CN CN202110407702.1A patent/CN113117241B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106345063A (en) * | 2016-08-31 | 2017-01-25 | 浙江和也健康科技有限公司 | Waist magnetic therapy device |
| CN206057340U (en) * | 2016-09-18 | 2017-03-29 | 姜涛 | A kind of diabetic therapy detection means |
| CN108210724A (en) * | 2018-02-05 | 2018-06-29 | 李春伸 | A kind of biological magnetic Chinese medicine for treating diabetes and preparation method thereof |
| CN110585163A (en) * | 2019-09-25 | 2019-12-20 | 万平 | Medical instrument |
| CN111408051A (en) * | 2020-03-31 | 2020-07-14 | 中国科学院合肥物质科学研究院 | Magnetic field generating device for adjusting blood glucose level and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113117241A (en) | 2021-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1032676C (en) | Low frequency rotation permanent magnetic field therapeutic device | |
| Lyle et al. | Calcium uptake by leukemic and normal T‐lymphocytes exposed to low frequency magnetic fields | |
| Belyaev et al. | Nonthermal effects of extremely high-frequency microwaves on chromatin conformation in cells in vivo-dependence on physical, physiological, and genetic factors | |
| Frankel | Biological effects of static magnetic fields | |
| US20020147424A1 (en) | Transdermal magnetic drug delivery system and method | |
| US20090093669A1 (en) | Magnetophoresis apparatus and method of use | |
| CN113117241B (en) | Magnetic field generating device for improving insulin level and sensitivity and application thereof | |
| Das | Demonstration of a non-RNA nucleolar fraction by silver staining | |
| CN105534908B (en) | A kind of tool Anaerobic response ability containing nucleic acid drug and radio therapy sensitization function liposome | |
| Krzyminiewski et al. | Focusing of Fe3O4 nanoparticles using a rotating magnetic field in various environments | |
| Masunaga et al. | Effect of bevacizumab combined with boron neutron capture therapy on local tumor response and lung metastasis | |
| CN111408051B (en) | Magnetic field generating device for adjusting blood glucose level and application thereof | |
| Markin et al. | Ion channel enzyme in an oscillating electric field | |
| Friedman et al. | The effects of chemotherapy and irradiation therapy on the differentiation of experimental tumors | |
| CN213698569U (en) | Multi-dimensional spiral three-dimensional magnetic array arrangement | |
| Sharma et al. | Effects of static magnetic field on the ultradian lateral leaflet movement rhythm in Desmodium gyrans | |
| Jackson et al. | Tethered-restraint system for blood collection from ferrets | |
| CN212739938U (en) | Automatic vending machine push rod processing automatic feeding device | |
| Tori et al. | Alterations of the microscopic structures of the human intestinal mucosa irradiated by means of small doses of x-rays | |
| Ono et al. | Effect of electroporation on cell killing by boron neutron capture therapy using borocaptate sodium (10B‐BSH) | |
| Mathewson et al. | Extremely low frequency (elf) vertical electric field exposure of rats: a search for growth, food consumption and blood metabolite alterations. Final report | |
| CN207143261U (en) | A kind of rotary cell cultivate reagent box | |
| Sanders et al. | The influence of intranuclear irradiation on the growth of HeLa cells in agitated fluid medium | |
| Pleše | Irregular patterns of polarographic maxima in surfactant dispersions | |
| Liebl et al. | Quantitative and binding-specific imaging of magnetic nanoparticle distributions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |